C4 THERAPEUTICS, INC.
Last · —$2.61-0.17 (-6.12%)live · yahoo · 1h ago
Market cap$321.10M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $35.9M |
|---|---|
| Operating income | $-115.2M |
| Net income | $-105.0M |
| Free cash flow | $-99.3M |
| Operating margin | -320.5% |
| Net margin | -292.1% |
| Return on equity | -40.9% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-26
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 53.1%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -292.1%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -274.6%
- Cash Runway Low — Cash runway ~0.8 years
- Accumulated Deficit High — Accumulated deficit / equity 288%
- Rd Intensity High — R&D/Revenue 290.0%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.21
Est. revenue
8.9M
Press & signals
- GlobeNewswire
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Documents
FormReporting forFiledFlags